Cargando…
Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
AIM: This multicenter study is the first one on Iranian children with very early onset ulcerative colitis (UC) and one of the few studies about the effect of biological therapy in children with UC under 7 years of age. BACKGROUND: Children with very early onset inflammatory bowel disease (IBD) are d...
Autores principales: | Rohani, Pejman, Alimadadi, Hosein, Abdollah Gorji, Fatemeh, Shahrokh, Shabnam, Zali, Mohammad Reza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817747/ https://www.ncbi.nlm.nih.gov/pubmed/35154605 |
Ejemplares similares
-
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009) -
Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021) -
An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016) -
Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017) -
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
por: Park, Sang Hyoung, et al.
Publicado: (2022)